Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA

This article was originally published in RPM Report

Executive Summary

The relabeling of Aransep and Procrit to address safety issues is taking longer than expected. There's nothing new about that. What is new is how FDA weighed in on the Congressional debate over coverage for the anemia therapies-and how the last step of the regulatory process is likely to play out.

Related Content

Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab
Pharma's New Follow-On Strategy
EPO Market Stabilizes, But For How Long?
The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Drug Approvals
Access and Evidence: Implications of the EPO Safety Debate (Part 2)
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit
Amgen's Biotech Shopping Spree
Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
Amgen Moves Beyond Proteins


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts